Mobile

This study aims to investigate the safety and efficacy of clofarabine, given in combination with cytarabine and liposomal daunorubicin, in the treatment of children with relapsed/refractory acute myel...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-009457-13

This study aims to investigate the safety and efficacy of clofarabine, given in combination with cytarabine and liposomal daunorubicin, in the treatment of children with relapsed/refractory acute myeloid leukemia (AML) Onderzoek naar de veiligheid en werkzaamheid van Clofarabine in combinatie met Cytarabine en Liposomaal Daunorubicine bij de behandeling van kinderen met recidief of refractaire Acute Myeloide Leukemie (AML)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To establish the recommended dose of clofarabine in combination with cytarabine and liposomal daunorubicin (DaunoXome®) in children with relapsed/refractory AML. Note: dosages of cytarabine and liposomal daunorubicin should be comparable to those used in the current Relapsed AML 2001/01 study (i.e. in the context of the FLAG/liposomal daunorubicin regimen).

Critère d'inclusion

  • Relapsed/refractory acute myeloid leukemia,acute myeloide leukemie

Liens